

参考文献 (今回のアンケート調査結果から)

Olson KB, et al. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin. Pharmacol. Ther 6:292-297, 1965.
McBride WG. Thalidomide and congenital abnormalities. Lancet II:1358,1961.
Lenz W. Thalidomide and congenital abnormalities. Lancet I:45,1962.
D'Amato RJ, Loughnan MS, Flynn E and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences USA, 91, 4082-4085, 1994.
Vacca A, Ribiatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F and Dommacco F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93, 3064-3073, 1999.
Sato N, Hattori Y, Du Wenlin, Taketo Yamada, Tamihiro Kamata, Tsunayuki Kakimoto, Shinichiro Okamoto, Chiharu Kawamura, Masahiro Kizaki, Naoki Shimada, Yukiko Ote, Jun-ichi Hata, Yasuo Ikeda. Elevated Level of Plasma Basic Fibroblast Growth Factor in Multiple Myeloma Correlates with Increased Disease Activity. Jpn. J. Cancer Res. 93:459-466, 2002.
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J and Barlogie B. Anti-tumor activity of Thalidomide in refractory multiple myeloma. New Engl J Med, 341, 1565-1571, 1999.
Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M & Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M & Ben-Bassat I. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug. Br J Haematol 2000;108:391-393.
Alexanian R and Weber D. Thalidomide for resistant and relapsing myeloma. Seminar in Hematology 2000;37:22-25.
Kakimoto T, et al. Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome. Jpn J Cancer Res. 2002;93:1029-1036.
落合直也ほか、治療抵抗性および再発多発性骨髄腫に対するサリドマイド療法の検討。臨床血液 43:1045-1049, 2002.
Eriksson T, Bjorkman S & Hoglund P. Clinical pharmacology of thalidomide. Eur J. Clin. Pharmacol. 57:365-376, 2001.
Tseng S, et al. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J. Amer. Acad. Dermatol. 35:969-979, 1996.

Raje N and Anderson KC. Thalidomide and immunomodulatory drugs as cancer therapy. <i>Curr. Opin. Oncol.</i> 14:635-640, 2002.
Neben K, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. <i>Br. J. Haematol.</i> 115:605-608, 2001.
Moreira AL, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. <i>J. Exp. Med.</i> 177:1675-1680, 1993.
D'Amato RJ, et al. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. <i>Semin. Oncol.</i> 28:597-601, 2001.
Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI and Anderson KC. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. <i>Blood</i> 96:2943-2950, 2000.
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. <i>Blood</i> 99:4525-30, 2002.
McHugh SM, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. <i>Clin. Exp. Immunol.</i> 99:160-167, 1995.
Haslett PA, et al. Thalidomide constimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. <i>J Exp Med</i> 187:1885-1892, 1998.
Davies FE, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> 98:210-216, 2001.
Barlogie B, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. <i>Blood</i> 98:492-494, 2001.
Barlogie B, et al. Long-term follow-up of 169 patients receiving thalidomide for advanced and refractory multiple myeloma. <i>Blood</i> 100:210a, 2002.
Grosbois B, et al. Thalidomide in the treatment of advanced multiple myeloma. A prospective study of 120 patients. <i>Blood</i> 98:689a, 2001.
Neben K, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. <i>Clin. Cancer Res.</i> 8:3377-3382, 2002.
Weber DM, et al. Thalidomide alone or with dexamethasone for multiple myeloma. <i>Blood</i> 94:2686a, 1999.
Larkin M. Low-dose thalidomide seems to be effective in multiple myeloma. <i>The Lancet</i> 1999;354:925
Durie BGM & Stepan DE. Low-dose thalidomide alone and in combination: long-term follow-up. <i>Blood</i> 98:688a, 2001.
Raza SN, et al. Durable response to thalidomide in relapsed/refractory multiple myeloma. <i>Blood</i> 96:726a, 2000.

Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. <i>Bone Marrow Transplantation</i> 28:1145-1150,2001.
Avigdor A, et al. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. <i>Leukemia and lymphoma</i> 42:683-687, 2001.
Blade J, et al. Thalidomide in multiple myeloma: lack of response in soft-tissue plasmacytomas. <i>Br. J. Haematol.</i> 113:424, 2001.
Schreiber S, et al. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. <i>Br. J. Haematol.</i> 110:605-609, 2000.
Neben K, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. <i>Clin. Cancer Res.</i> 7:2675-2681, 2001.
Neben K, et al. Polymorphisms of the tumor necrosis factor- β gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. <i>Blood</i> 100:2263-2267, 2002.
Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. <i>N Engl J Med.</i> 343:972-3, 2000.
Osman K, Comenzo R and Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. <i>N. Engl. J. Med.</i> , 344, 1951-1952,2001.
Urbauer E, et al. Thromboembolic events during treatment with thalidomide. <i>Blood</i> 99:4247, 2002.
Zangari M, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. <i>Blood</i> 100:1168-1171, 2002.
Rajkumar SV, Hayman Suzanne, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA & Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. <i>J. Clin. Oncol.</i> 20:4319-4323,2002.
Dimopoulos MA, Zervas K, Kouvatsas G. Thalidomide and dexamethasone combination for refractory multiple myeloma. <i>Ann Oncol.</i> 12:991-995, 2001.
Zangari M, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. <i>Blood</i> 98:1614-1615,2001.
Weber DM, Rankin K, Gavino M, Delasalle K & Alexanian R. Thalidomide with dexamethasone for resistant multiple myeloma. <i>Blood</i> 96:719a,2000.
Palumbo A, Giaccone L, Bringhen S. Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients. <i>Blood</i> 98:683a,2001.
Tosi P, Zamagni E, Cellini C. Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractory multiple myeloma. <i>Blood</i> 98:687a, 2001.
Rajkumar SV, Dispenzieri A., Fonseca R, Lacy MQ, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA & Witzig TE. Thalidomide for previously untreated indolent or smoldering multiple myeloma. <i>Leukemia</i> 15:1274-1276, 2001.
Shaughnessy J, et al. Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. <i>Blood</i> 96:2485a, 2000.

Barlogie B, Zangari M, Spencer G. Thalidomide in the management of multiple myeloma. <i>Sem Hematol</i> 38:250-259, 2001.
Moehler TM, Neben K, Brenner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. <i>Blood</i> 98:3846, 2001.
Kropff MH, Innig G, Mitterer M. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide in primary refractory or relapsed multiple myeloma. <i>Blood</i> 96:168a, 2000.
Ahmad I, et al. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. <i>Bone Marrow Transplantation</i> 29:577-580, 2002.
Munshi N, et al. Peripheral blood stem cell collection after CAD+G-CSF as part of total therapy II in newly diagnosed multiple myeloma: Influence of thalidomide administration. <i>Blood</i> 94:578a, 1999.
Alexanian R, Weber D, Giralt S and Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. <i>Annal. Oncol.</i> 13:1116-1119, 2002.
Brinker B, Waller EK, Langston AA, Redei I, Smith KJ, Bucur SZ, Winton E, Lyles R, Heffner LT, Lonial S. Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma. <i>Blood</i> 100:178a, 2002.
Raje N & Anderson K. Thalidomide and immunomodulatory drugs as cancer therapy. <i>Curr. Opin. Oncol.</i> 14:635-640, 2002.
Richardson PG, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood</i> 100:3063-3067, 2002.
Richardson P, et al. A phase II multicenter study of the proteasome inhibitor Bortezomib (VELCADE, formerly PS-341) in multiple myeloma patients with relapsed/refractory disease. <i>Blood</i> 100:104a, 2002.
Mesa RA, et al. A phase II trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. <i>Blood</i> online publication Nov 27, 2002.
Elliott MA, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. <i>Br J Haematol.</i> 117:288-296, 2002.
Raza A, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. <i>Blood</i> 98:958-965, 2001.